PCA3 - Prostate Cancer Biomarker by Transcription-Mediated Amplification
Ordering Recommendation
Do not use for initial prostate cancer screening. Preferred test is total prostate specific antigen (PSA) (0070121) in conjunction with digital rectal exam. The PCA3 test may be useful, in conjunction with other patient information, to aid in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies and for whom a repeat biopsy would be recommended by a urologist based on current standard of care.
Submit With Order
Transcription-mediated Amplification
Tue, Fri
3-6 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collection must follow Digital Rectal Exam (DRE).  
20-30 mL first catch urine following DRE in preservative-free urine collection cup.  
Specimen Preparation
Invert urine container 5 times to mix, then transfer 2.5 mL urine to Progensa PCA3 Urine Specimen Transport Tube (ARUP Supply #45682). Liquid level must be between black lines on transport tube. Cap transport tube and invert 5 times to mix. Transport tubes are available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Unacceptable Conditions
Urine in original collection cup. Specimens in APTIMA Combo 2 Urine Specimen transport media (ARUP Supply #28908).  
Ambient: 5 days; Refrigerated: 5 days; Frozen: 3 months  
Reference Interval
PCA3/PSA ratio score greater than or equal to 25 is considered positive.
Interpretive Data
The Progensa PCA3 assay is an in vitro nucleic acid amplification test utilizing target capture, transcription-mediated amplification, and a hybridization-protection assay for amplicon detection. PCA3 Score is calculated as the ratio of PCA3 RNA copies to PSA RNA copies, multiplied by 1000.

Sensitivity and Specificity:
77.5 percent and 57.1 percent respectively (relative to prostate biopsy outcome), based on a PCA3 score cutoff value of 25.

This test should not be used for men with a result of Atypical Small Acinar Proliferation (ASAP) on their most recent biopsy. Performance has not been established in men who undergo a repeat biopsy less than 3 months or more than 7 years after their most recent negative biopsy. The effect of medications known to influence serum PSA levels or therapeutic and/or diagnostic procedures such as prostatectomy, radiation, or prostate biopsy that may impact the viability of prostatic tissue and PCA3 Score have not been evaluated.

Values obtained with different assay methods or kits cannot be used interchangeably. Results should be interpreted in correlation with clinical history and other relevant data.
CPT Code(s)
Component Test Code*Component Chart Name
2010103PCA3 by TMA - Score
2010104PCA3 by TMA - Result
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • PCA3 score
  • PCA3/PSA ratio